Showing 1591-1600 of 1732 results for "".
- Results for Cryopreserved Gene Therapy Formulation for Treatment of Early-Onset Metachromatic Leukodystrophyhttps://practicalneurology.com/news/results-for-cryopreserved-gene-therapy-formulation-for-treatment-of-early-onset-metachromatic-leukodyphy/2469057/In initial results from the A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (NCT03392987) of a cryopreserved gene therapy formulation (OTL-200: Orchard Therapeutics, Boston, MA)
- Perampanel Monotherapy May Provide Seizure Freedomhttps://practicalneurology.com/news/perampanel-monotherapy-may-provide-seizure-freedom/2468937/In a phase 3 study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) used as monotherapy for new-onset or untreated partial-onset seizures (POS) provided seizure freedom for 63% (46/73) of people treated (95% CI: 50.9–74.0). In an open-label descriptive study (
- Feasibility of Leqembi Treatment Supported by Real-World Data from Specialty Memory Clinichttps://practicalneurology.com/news/feasibility-of-leqembi-treatment-supported-by-real-world-data-from-specialty-memory-clinic/2474841/One specialty memory clinic found that it was feasible and manageable to treat people with early symptomatic Alzheimer disease (AD) using Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA), according to results of a retrospective analysis published in JAMA Neurology. Th
- Headset for EEG-Assessment of Seizure Activity Cleared by FDAhttps://practicalneurology.com/news/headset-for-eeg-assessment-of-seizure-activity-cleared-by-fda/2470494/The Food and Drug Administration (FDA) has granted 510(k) clearance to ONE (Zeto, Santa Clara, CA), a headset that records electroencephalography (EEG) signals and other patient data using artificial-intelligence (AI)–based triage tools to monitor seizure activity in critical or emergency c
- Dayvigo Improves Sleep Factors in Patients with COPDhttps://practicalneurology.com/news/dayvigo-improves-sleep-factors-in-patients-with-copd/2470493/Study results presented at the 2024 SLEEP meeting of the Associated Professional Sleep Societies demonstrated that Dayvigo (lemborexant; Easai, Woodcliff, NJ), a dual-orexin receptor antagonist Food and Drug Administration (FDA)-approved for the treatment of insomnia in adults, improved sleep ons
- “Giants of MS” Award Presented to 7 MS Leaders at 2024 CMSC Annual Meetinghttps://practicalneurology.com/news/giants-of-ms-award-presented-to-7-ms-leaders-at-2024-cmsc-annual-meeting/2470488/Several leaders in different areas of multiple sclerosis (MS) research received the “Giants of MS” award for their contributions and achievements. One recipient was selected for each of the 7 award categories, including: Advanced Care Provider, Mental Health, Neurology, Nursing, Pharm
- New Scholarship for Medical Students Interested in Neurology Establishedhttps://practicalneurology.com/news/new-scholarship-for-medical-students-interested-in-neurology-established/2470434/Ameer E. Hassan, DO, a professor of neurology at the University of Texas and a practicing neurologist at the Valley Baptist Medical Center-Harlingen, has established a new educational funding opportunity: the Dr. Ameer Hassan Scholarship for Medical Students. The scholarship consists of a one-tim
- Promising Results from Study of Stem Cell Transplantation in People with Multiple Sclerosis Publishedhttps://practicalneurology.com/news/promising-results-from-study-of-stem-cell-transplantation-in-people-with-multiple-sclerosis-published/2470351/One-year results from a phase I clinical trial (NCT03282760) demonstrated the feasibility, safety, and tolerability of intracerebroventricular (ICV) human neural stem/progenitor cell (hNSC) transplantation in patients with secondary progressive multiple sclerosis (SPMS). Results were published in
- Probiotics May Have Beneficial Effects in Patients with Parkinson Diseasehttps://practicalneurology.com/news/probiotics-may-have-beneficial-effects-in-patients-with-parkinson-disease/2470277/Probiotic use may be associated with improved Parkinson disease (PD) symptoms, according to studies presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders. Results from one study suggest that prolonged probiotic use may have potential as a therapy for pat
- Open Label Extension Trial of Ozanimod Confirms Disease Stability at 6-7 Yearshttps://practicalneurology.com/news/open-label-extension-trial-of-ozanimod-confirms-disease-stability-at-6-7-years/2470126/Data from 2 phase 3 trials and one open label extension study (OLE) used to evaluate long-term efficacy by patient age group were presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRI